ReviewCancer metastasis reviews2026
Engineered bone matrix models for understanding breast cancer skeletal metastasis.
Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The osteoporotic niche as a metabolic sanctuary for breast cancer dormancy and reactivation: A mechanistic perspective.iScience · 2026Review
- Modeling and targeting the hostile physicochemical niche in bone metastasis: from experimental platforms to niche-directed therapy.Frontiers in cell and developmental biology · 2026Review
- Advancing the 3Rs in bone tissue engineering: emergingFrontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Bone is the most common site of metastasis in patients with advanced breast cancer and serves as a reservoir from which secondary metastases often originate. While research has traditionally focused on understanding the biochemical signals involved in bone metastasis, bone matrix changes are inextricably linked with its pathogenesis as well. Indeed, decreased bone matrix density is both a symptom of late-stage disease and a risk factor for metastasis formation. Vice versa, raising bone density protects against metastasis. How bone matrix controls metastatic outgrowth and progression and which biochemical or biophysical mechanisms are involved in these processes is poorly understood due in part to limitations in current models of bone metastasis. In this review, we discuss the role of bone matrix in the microenvironmental regulation of bone metastasis and its effect on mechanosignaling and highlight current and future engineered model systems that have the potential to yield new mechanistic insights to advance the clinical prognosis of breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.